Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Cash & Equivalents (2016 - 2025)

AtriCure (ATRC) has disclosed Cash & Equivalents for 16 consecutive years, with $167.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 36.43% to $167.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $167.4 million, a 36.43% increase, with the full-year FY2025 number at $167.4 million, up 36.43% from a year prior.
  • Cash & Equivalents was $167.4 million for Q4 2025 at AtriCure, up from $147.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $167.4 million in Q4 2025 to a low of $28.1 million in Q1 2022.
  • A 5-year average of $84.6 million and a median of $79.0 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 292.26% in 2021, then tumbled 67.04% in 2022.
  • AtriCure's Cash & Equivalents stood at $43.7 million in 2021, then surged by 33.09% to $58.1 million in 2022, then soared by 45.11% to $84.3 million in 2023, then soared by 45.56% to $122.7 million in 2024, then soared by 36.43% to $167.4 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's Cash & Equivalents are $167.4 million (Q4 2025), $147.9 million (Q3 2025), and $117.8 million (Q2 2025).